INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Narrative review / 2013

Weight loss is a key treatment for NAFLD, with ~5% loss improving steatosis and ~10% needed to improve steatohepatitis.

This review outlines nonalcoholic fatty liver disease (NAFLD), ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), noting obesity, insulin resistance, type 2 diabetes mellitus, and dyslipidemia as major risk factors. Weight loss is a cornerstone of therapy, where ~5% weight loss is believed to improve steatosis and ~10% is necessary to improve steatohepatitis. Pharmacologic agents like vitamin E and thiazolidinediones have also demonstrated promise in select patient subgroups.

Study type
Narrative review
Who was studied
Individuals with nonalcoholic fatty liver disease (NAFLD)
What was measured
Pathology, risk factors, diagnosis, and management of NAFLD and NASH

THE PAPER

Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals.

Masuoka HC, Chalasani N. Ann N Y Acad Sci, 2013.

PubMed 23363012 ↗DOI 10.1111/nyas.12016 ↗

Heart & arteriesDiabetes & blood sugarNutrients & adequacyWeight & appetite

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.